NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF GALLIUM ARSENIDE (CAS NO. 1303-00-0) IN F344/N RATS AND B6C3F1 MICE (INHALATION STUDIES)

NTP Technical Report on the Toxicology and Carcinogenesis Studies Series

Volumn TR-492, Issue , 2000, Pages 1-313

  Program, National Toxicology ^a   Roycroft, J H ^a   Bucher, J R ^a   Chapin, R E ^a   Haseman, J K ^a   Herbert, R A ^a,c   Maronpot, R R ^a   Orzech, D P ^a   Rao, G N ^a   Smith, C S ^a   Travlos, G S ^a   Witt, K L ^a   Chou, B J ^a   Dill, J A ^a   Grumbein, S L ^a,d   Mast, T J ^a   Mellick, P W ^a   Mellinger, K ^a   Ragan, H A ^a   Renne, R A ^a   Su, Y F ^a   Westerberg, R B ^a   Hardisty, J F ^a   Brecher, S ^a   Hildebrandt, P K ^a   Cattley, R ^b   Dixon, D ^c   Jokinen, M P ^e   Nyska, A ^c   Shackelford, C C ^f   Hailey, J R ^c   Miller, R A ^d   Morris, R W ^a   Kendrick, D E ^a   McGowan, K P ^a   Scott, J T ^a   Gunnels, S R ^a   Harper, L M ^a   Macri Hanson, A M ^a   Yount, P A ^a   more..

^a PATHCO Inc ^*

^b Chemical Industry Institute of Toxicology

^c National Toxicology Program

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^e Pathology Associates International

^f EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0345563843     PISSN: 23788917     EISSN: 23788925     Source Type: Book Series    
DOI: None     Document Type: Review

References (137)

1. Agency for Toxic Substances and Disease Registry (ATSDR) (1993). Toxicological Profile for Arsenic. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry.
2. Aizawa, Y., Takata, T., Karube, H., Tatsumi, H., Inokuchi, N., Kotani, M., and Chiyotani, K. (1993). Magnetometric evaluation of the effects of gallium arsenide on the clearance and relaxation of iron particles. Ind. Health 31, 143-153.
3. American Conference of Governmental Industrial Hygienists (ACGIH) (1998). Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH.
4. Ashby, J., and Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res. 257, 229-306.
5. Bailer, A.J., and Portier, C.J. (1988). Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 44, 417-431.
6. Battelle Pacific Northwest Laboratories (1990a). Thirteen-week subchronic inhalation toxicity study report of gallium oxide in rats. Final report (NIH No. N01-ES-85211); November 1990.
7. Battelle Pacific Northwest Laboratories (1990b). Thirteen-week subchronic inhalation toxicity study report of gallium oxide in mice. Final report (NIH No. N01-ES-85211); December 1990.
8. Battelle Pacific Northwest Laboratories (1990c). Inhalation developmental toxicology studies: Gallium arsenide in mice and rats. Final report (NIH No. N01-ES-70153); December 1990.
9. Bernstein, L.R. (1998). Mechanisms of therapeutic activity for gallium. Am. Soc. Pharmacol. Exp. Ther. 50, 665-682.
10. Bieler, G.S., and Williams, R.L. (1993). Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity. Biometrics 49, 793-801.
11. Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In Handbook of Carcinogen Testing (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ.
12. Brecher, G., and Schneiderman, M. (1950). Time saving device for the counting of reticulocytes. Am. J. Clin. Pathol. 20, 2079-2084.
13. Brodsky, M.H. (1990). Progress in gallium arsenide semiconductors. Sci. Am. 262, 68-75.
14. Brucer, M., Andrews, G.A., and Bruner, H.D. (1953). A study of gallium. Radiology 61, 534-613.
15. Burns, L.A., and Munson, A.E. (1993). Gallium arsenide selectively inhibits T cell proliferation and alters expression of CD25 (IL-2R/p55). J. Pharmacol. Exp. Ther. 265, 178-186.
16. Burns, L.A., Sikorski, E.E., Saady, J.J., and Munson, A.E. (1991). Evidence for arsenic as the immunosuppressive component of gallium arsenide. Toxicol. Appl. Pharmacol. 110, 157-169.
17. Burns, L.A., McCay, J.A., Brown, R., and Munson, A.E. (1993). Arsenic in the sera of gallium arsenide-exposed mice inhibits bacterial growth and increases host resistance. J. Pharmacol. Exp. Ther. 265, 795-800.
18. Burns, L.A., LeVier, D.G., and Munson, A.E. (1994a). Immunotoxicology of Arsenic. In Immunotoxicology and Immunopharmacology (J.H. Dean, M.I. Luster, A.E. Munson, and I. Kimber, Eds.), pp. 213-225. Raven Press, Ltd., New York.
19. Burns, L.A., Spriggs, T.L., Fuchs, B.A., and Munson, A.E. (1994b). Gallium arsenide-induced increase in serum corticosterone is not responsible for suppression of the IgM antibody response. J. Pharmacol. Exp. Ther. 268, 740-746.
20. Chitambar, C.R., and Zivkovic, Z. (1987). Inhibition of hemoblogin production by transferrin-gallium. Blood 69, 144-149.
21. Code of Federal Regulations (CFR) (1991). 21, Part 58.
22. Cox, D.R. (1972). Regression models and life-tables. J. R. Stat. Soc. B34, 187-220.
23. Crawford, B.D. (1985). Perspectives on the somatic mutation model of carcinogenesis. In Advances in Modern Environmental Toxicology. Mechanisms and Toxicity of Chemical Carcinogens and Mutagens (M.A. Mehlman, W.G. Flamm, and R.J. Lorentzen, Eds.), pp. 13-59. Princeton Scientific Publishing Co., Inc., Princeton, NJ.
24. Dixon, W.J., and Massey, F.J., Jr. (1951). Introduction to Statistical Analysis, 1st ed., pp. 145-147. McGraw-Hill Book Company, Inc., New York.
25. Dudley, H.C. (1949). Determination of gallium in biological materials. J. Pharmacol. Exp. Ther. 95, 482-486.
26. Dudley, H.C., and Levine, M.D. (1949). Studies of the toxic action of gallium. J. Pharmacol. Exp. Ther. 95, 487-493.
27. Dudley, H.C., and Marrer, H.H. (1952). Studies of the metabolism of gallium. III. Deposition in and clearance from bone. J. Pharmacol. Exp. Ther. 106, 129.
28. Dudley, H.C., Maddox, G.E., and LaRue, H.C. (1949). Studies of the metabolism of gallium. J. Pharmacol. Exp. Ther. 96, 135-138.
29. Dudley, H.C., Henry, K.E., and Lindsey, B.F. (1952). Studies of the toxic action of gallium. II. J. Pharmacol. Exp. Ther. 98, 409-417.
30. Dunn, O.J. (1964). Multiple comparisons using rank sums. Technometrics 6, 241-252.
31. Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096-1121.
32. Ferm, V.H., and Carpenter, S.J. (1970). Teratogenic and embryopathic effects of indium, gallium, and germanium. Toxicol. Appl. Pharmacol. 16, 166-170.
33. Flora, S.J.S., and Das Gupta, S. (1992). Effect of single gallium arsenide exposure on some biochemical variables in porphyrin metabolism in rats. J. Appl. Toxicol. 12, 333-334.
34. Flora, S.J.S., Dube, S.N., Vijayaraghavan, R., and Pant, S.C. (1997). Changes in certain hematological and physiological variables following single gallium arsenide exposure in rats. Biol. Trace Elem. Res. 58, 197-208.
35. Genium's Handbook of Safety, Health, and Environmental Data for Common Hazardous Substances (1999), pp. 1734-1735. McGraw-Hill, New York.
36. Gibson, D.P., Brauninger, R., Shaffi, H.S., Kerckaert, G.A., LeBoeuf, R.A., Isfort, R.J., and Aardema, M.J. (1997). Induction of micronuclei in Syrian hamster embryo cells: Comparison to results in the SHE cell transformation assay for National Toxicology Program test chemicals. Mutat. Res. 392, 61-70.
37. Goering, P.L., and Rehm, S. (1990). Inhibition of liver, kidney, and erythrocyte *-aminolevulinic acid dehydratase (porphobilinogen synthase) by gallium in the rat. Environ. Res. 53, 135-151.
38. Goering, P.L., Maronpot, R.R., and Fowler, B.A. (1988). Effect of intratracheal gallium arsenide administration on *-aminolevulinic acid dehydratase in rats: Relationship to urinary excretion of aminolevulinic acid. Toxicol. Appl. Pharmacol. 92, 179-193.
39. Gomez, M., Sanchez, D.J., Domingo, J.L., and Corbella, J. (1992). Developmental toxicity evaluation of gallium nitrate in mice. Arch. Toxicol. 66, 188-192.
40. Gonsebatt, M.E., Vega, L., Salazar, A.M., Montero, R., Guzman, P., Blas, J., Del Razo, L.M., Garcia-Vegas, G., Albores, A., Cebrian, M.E., Kelsh, M., and Ostrosky-Wegman, P. (1997). Cytogenetic effects in human exposure to arsenic. Mutat. Res. 386, 219-228.
41. Greenspan, B.J., Dill, J.A., Mast, T.J., Leach, C.L., Stoney, K.H., and Goehl, T.J. (1990). Lung burdens and clearance of gallium arsenide (GaAs) in rats. Conference on Particle-Lung Interactions, Rochester, NY, May 17-19, 1990.
42. Greenspan, B.J., Dill, J.A., Mast, T.J., Chou, B.J., Stoney, K.H., Morrissey, R., and Roycroft, J. (1991). Lung clearance of inhaled gallium arsenide (GaAs). Toxicologist, 11, 234. (Abstr.)
43. Gurr, J.-R., Liu, F., Lynn, S., and Jan, K.-Y. (1998). Calcium-dependent nitric oxide production is involved in arsenite-induced micronuclei. Mutat. Res. 416, 137-148.
44. Harrison, R.J. (1986). Gallium arsenide. In Occupational Medicine: The Microelectronics Industry (J. LaDou, Ed.), Vol. 1, pp. 49-58. Hanley & Belfus, Inc., Philadelphia.
45. Hartmann, A., and Speit, G. (1996). Effect of arsenic and cadmium on the persistence of mutagen-induced DNA lesions in human cells. Environ. Mol. Mutagen. 27, 98-104.
46. Hartwig, A. (1995). Current aspects in metal genotoxicity. Biometals. 8, 3-11.
47. Hawley's Condensed Chemical Dictionary (1997). 13th ed. (R.J. Lewis, Sr., Ed.), pp. 527-528. Van Nostrand Reinhold, New York.
48. Hei, T.K., Liu, S.X., and Waldren, C. (1998). Mutagenicity of arsenic in mammalian cells: Role of reactive oxygen species. Proc. Natl. Acad. Sci U.S.A. 95, 8103-8107.
49. Heinrich, U. (1996). Comparative response to long-term particle exposure among rats, mice, and hamsters. In Particle Overload in the Rat Lung and Lung Cancer: Implications for Human Risk Assessment, (J.L. Mauderly and R.J. McCunney, Eds.), pp. 51-71. Taylor & Francis, Washington, DC.
50. Hollander, M., and Wolfe, D.A. (1973). Nonparametric Statistical Methods, pp. 120-123. John Wiley and Sons, New York.
51. Hood, R.D., and Bishop, S.L. (1972). Teratogenic effects of sodium arsenate in mice. Arch. Environ. Health 24, 62-65.
52. Huang, R.-N., Ho, I.-C., Yih, L.-H., and Lee, T.-C. (1995). Sodium arsenite induces chromosome endoreduplication and inhibits protein phosphatase activity in human fibroblasts. Environ. Mol. Mutagen. 25, 188-196.
53. Integrated Laboratory Systems (ILS) (1990). Micro-nucleus Data Management and Statistical Analysis Software, Version 1.4. ILS, P.O. Box 13501, Research Triangle Park, NC 27707.
54. International Agency for Research on Cancer (IARC) (1980). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Some Metals and Metallic Compounds, Vol. 23, p. 89. IARC, Lyon, France.
55. International Agency for Research on Cancer (IARC) (1987). IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity: An Updating of Volumes 1 to 42, pp. 100-106, (Suppl. 7). IARC, Lyon, France.
56. Jha, A.N., Noditi, M., Nilsson, R., and Natarajan, A.T. (1992). Genotoxic effects of sodium arsenite on human cells. Mutat. Res. 284, 215-221.
57. Jonckheere, A.R. (1954). A distribution-free k-sample test against ordered alternatives. Biometrika 41, 133-145.
58. Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
59. Kelsen, D.P., Alcock, N., Yeh, S., Brown, J., and Young, C. (1980). Pharmacokinetics of gallium nitrate in man. Cancer 46, 2009-2013.
60. Kirk-Othmer Encyclopedia of Chemical Technology (1980). 3rd ed. (M. Grayson, Ed.), Vol. 3, p. 248, Vol. 11, p. 619. John Wiley & Sons, New York.
61. Krakoff, I.H., Newman, R.A., and Goldberg, R.S. (1979). Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer 44, 1722-1727.
62. Labbe, R.F., and Lamon, J.M. (1987). Porphyrins and disorders of porphyrin metabolism. In Fundamentals of Clinical Chemistry, 3rd ed. (N.W. Teitz, Ed.), pp. 825-841. W.B. Saunders Co., Philadelphia.
63. Labbe, R.F., and Rettmer, R.L. (1989). Zinc protoporphyrin: A product of iron-deficient erythropoiesis. Sem. in Hemat. 26, 40-46.
64. Lee, T.-C., Huang, R.Y., and Jan, K.Y. (1985a). Sodium arsenite enhances the cytotoxicity, clastogenicity, and 6-thioguanine-resistant mutagenicity of ultraviolet light in Chinese hamster ovary cells. Mutat. Res. 148, 83-89.
65. Lee, T.-C., Oshimura, M., and Barrette, J.C. (1985b). Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis 6, 1421-1426.
66. Lee, T.-C., Lee, K.C., Tzeng, Y.J., Huang, R.Y., and Jan, K.Y. (1986). Sodium arsenite potentiates the clastogenicity and mutagenicity of DNA crosslinking agents. Environ. Mutagen. 8, 119-128.
67. McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. JNCI 76, 283-289.
68. MacGregor, J.T., Wehr, C.M., Henika, P.R., and Shelby, M.D. (1990). The in vivo erythrocyte micronucleus test: Measurement at steady state increases assay efficiency and permits integration with toxicity studies. Fundam. Appl. Toxicol. 14, 513-522.
69. Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. Toxicol. Pathol. 10, 71-80.
70. Martinez, G., Cebrian, M., Chamorro, G., and Jauge, P. (1983). Urinary porphyrins as an indicator of arsenic exposure in rats. Proc. West. Pharmacol. Soc. 26, 171-174.
71. Mast, T.J., Dill, J.A., Greenspan, B.J., Evanoff, J.J., Morrissey, R.E., and Schwetz, B.A. (1991). The developmental toxicity of inhaled gallium arsenide in rodents. Teratology 43, 455-456 (Abstr.).
72. The Merck Index (1996). 12th ed. (S. Budavari, Ed.), p. 738. Merck and Company, Whitehouse Station, NJ.
73. Miller, J.A., and Miller, E.C. (1977). Ultimate chemical carcinogens as reactive mutagenic electrophiles. In Origins of Human Cancer (H.H. Hiatt, J.D. Watson, and J.A. Winsten, Eds.), pp. 605-627. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
74. Morrison, D.F. (1976). Multivariate Statistical Methods, 2nd ed., pp. 170-179. McGraw-Hill Book Company, New York.
75. Morrow, P.E. (1986). The setting of particulate exposure levels for chronic inhalation toxicity studies. J. Am. Coll. Toxicol. 6, 533-544.
76. National Cancer Institute (NCI) (1976). Guidelines for Carcinogen Bioassay in Small Rodents. Technical Report Series No. 1. NIH Publication No. 76-801. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD.
77. National Institute for Occupational Safety and Health (NIOSH) (1985). Hazard Assessment of the Electronic Component Manufacturing Industry. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, Cincinnati, OH.
78. National Institute for Occupational Safety and Health (NIOSH) (1987). Request for Assistance in Reducing the Potential Risk of Developing Cancer from Exposure to Gallium Arsenide in the Microelectronics Industry. NIOSH, Cincinnati, OH.
79. National Institutes of Health (NIH) (1978). Open Formula Mouse and Rat Ration (NIH-07). Specification NIH-11-1335. U.S. Department of Health, Education, and Welfare, Public Health Service, NIH, Bethesda, MD.
80. National Toxicology Program (NTP) (1987). Technical Protocol for Sperm Morphology and Vaginal Cytology Evaluations in Toxicity Testing for Rats and Mice, 10/31/82 version (updated December 1987). Research Triangle Park, NC.
81. 1 Mice (Feed Studies). Technical Report Series No. 416. NIH Publication No. 93-3147. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
82. 1 Mice (Inhalation Studies). Technical Report Series No. 421. NIH Publication No. 93-3152. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
83. 1 Mice (Inhalation Studies). Technical Report Series No. 453. NIH Publication No. 96-3369. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
84. 1 Mice (Inhalation Studies). Technical Report Series No. 451. NIH Publication No. 96-3367. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
85. 1 Mice (Inhalation Studies). Technical Report Series No. 454. NIH Publication No. 96-3370. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
86. 1 Mice (Inhalation Studies). Technical Report Series No. 461. NIH Publication No. 97-3377. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
87. National Toxicology Program (NTP) (1998a). Report on Carcinogens, Eighth Edition. pp. 17-19. U.S. Department of Health and Human Services. National Institute of Environmental Health Sciences, Research Triangle Park, NC.
88. 1 Mice. Analytical Sciences, Inc., Durham, NC.
89. 1 Mice (Inhalation Studies). Technical Report Series No. 471. NIH Publication No. 98-3961. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
90. National Toxicology Program (NTP) (1998d). Tumor Incidence in Control Animals by Route and Vehicle of Administraton in F344/N Rats. Analytical Sciences, Inc., Durham, NC.
91. Ohyama, S., Ishinishi, N., Hisanaga, A., and Yamamoto, A. (1988). Comparative chronic toxicity, including tumorigenicity, of gallium arsenide and arsenic trioxide intratracheally instilled into hamsters. Appl. Organometallic Chem. 2, 333-337.
92. Omura, M., Tanaka, A., Hirata, M., Zhao, M., Makita, Y., Inoue, N., Gotoh, K., and Ishinishi, N. (1996a). Testicular toxicity of gallium arsenide, indium arsenide, and arsenic oxide in rats by repetitive intratracheal instillation. Fundam. Appl. Toxicol. 32, 72-78.
93. Omura, M., Hirata, M., Tanaka, A., Zhao, M., Makita, Y., Inoue, N., Gotoh, K., and Ishinishi, N. (1996b). Testicular toxicity evaluation of arsenic-containing binary compound semiconductors, gallium arsenide, and indium arsenide, in hamsters. Toxicol. Lett. 89, 123-129.
94. Patty's Industrial Hygiene and Toxicology (1994). 4th ed. (G.D. Clayton and F.E. Clayton, Eds.), Vol. 2C, pp. 1879-2013. John Wiley and Sons, Inc., New York.
95. Petkof, B. (1980a). Gallium. In Mineral Facts and Problems, pp. 323-328. Bureau of Mines Bulletin 671. U.S. Department of the Interior.
96. Petkof, B. (1980b). Gallium. In Minerals Yearbook, Vol. 1, Metals and Minerals. Bureau of Mines, U.S. Department of the Interior.
97. Piegorsch, W.W., and Bailer, A.J. (1997). Statistics for Environmental Biology and Toxicology, Section 6.3.2. Chapman and Hall, London.
98. Pierson, B., Van Wagenen, S., Nebesny, K.W., Fernando, Q., Scott, N., and Carter, D.E. (1989). Dissolution of crystalline gallium arsenide in aqueous solutions containing complexing agents. Am. Ind. Hyg. Assoc. J. 50, 455-459.
99. Portier, C.J., and Bailer, A.J. (1989). Testing for increased carcinogenicity using a survival-adjusted quantal response test. Fundam. Appl. Toxicol. 12, 731-737.
100. Portier, C.J., Hedges, J.C., and Hoel, D.G. (1986). Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments. Cancer Res. 46, 4372-4378.
101. Ramirez, P., Eastmond, D.A., Laclette, J.P., and Ostrosky-Wegman, P. (1997). Disruption of micro-tubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Mutat. Res. 386, 291-298.
102. Rasey, J.S., Nelson, N.J., and Larson, S.M. (1981). Relationship of iron metabolism to tumor cell toxicity of stable gallium salts. Int. J. Nucl. Med. Biol. 8, 303-313.
103. Rasmussen, R.E., and Menzel, D.B. (1997). Variation in arsenic-induced sister chromatid exchange in human lymphocytes and lymphoblastoid cell lines. Mutat. Res. 386, 299-306.
104. Roschina, T.A. (1966). Toxicological characteristics of indium antimonide and gallium arsenide-A group of new semiconductors. Gig. Tr. Prof. Zabol. 10, 30.
105. Rosen, F., Roberts, N.R., Budnick, L.E., and Nichol, C.A. (1959). Corticosteroids and transaminase activity: The specificity of the glutamic-pyruvic transamine response. Endocrin 65, 256-264.
106. Rosen, F., Roberts, N.R., and Nichol, C.A. (1959). Glucocorticosteroids and transaminase activity: I. Increased activity of glutamic-pyruvic transaminase in four conditions associated with gluconeogenesis. J. Biol. Chem. 234, 476-480.
107. Rosner, M.H., and Carter, D.E. (1987). Metabolism and excretion of gallium arsenide and arsenic oxides by hamsters following intratracheal instillation. Fundam. Appl. Toxicol. 9, 730-737.
108. Sax's Dangerous Properties of Industrial Materials (1992). 8th ed. (R.J. Lewis, Sr., Ed.), pp. 1776-1777. Van Nostrand Reinhold, New York.
109. Scott, N., Carter, D.E., and Fernando, Q. (1989). Reaction of gallium arsenide with concentrated acids: Formation of arsine. Am. Ind. Hyg. Assoc. J. 50, 379-381.
110. Sheehy, J.W., and Jones, J.H. (1993). Assessment of arsenic exposures and controls in gallium arsenide production. Am. Ind. Hyg. Assoc. J. 54, 61-69.
111. Shelby, M.D., and Witt, K.L. (1995). Comparison of results from mouse bone marrow chromosome aberration and micronucleus tests. Environ. Mol. Mutagen. 25, 302-313.
112. Shelby, M.D., Erexson, G.L., Hook, G.J., and Tice, R.R. (1993). Evaluation of a three-exposure mouse bone marrow micronucleus protocol: Results with 49 chemicals. Environ. Mol. Mutagen. 21, 160-179.
113. Shirley, E. (1977). A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics 33, 386-389.
114. 1 mice. Fundam. Appl. Toxicol. 13, 843-858.
115. Sikorski, E.E., Burns, L.A., McCoy, K.L., Stern, M., and Munson, A.E. (1991). Suppression of splenic accessory cell function in mice exposed to gallium arsenide. Toxicol. Appl. Pharmacol. 110, 143-156.
116. Straus, D.S. (1981). Somatic mutation, cellular differentiation, and cancer causation. JNCI 67, 233-241.
117. Tarone, R.E. (1975). Tests for trend in life table analysis. Biometrika 62, 679-682.
118. Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.K., Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B., and Minor, R. (1987). Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 236, 933-941.
119. Tinwell, H., Stephens, S.C., and Ashby, J. (1991). Arsenite as the probable active species in the human carcinogenicity of arsenic: Mouse micronucleus assays on Na and K arsenite, orpiment, and Fowler's solution. Environ. Health Perspect. 95, 205-210.
120. V e g a, L., G o n s e b a t t, M. E., a n d Ostrosky-Wegman, P. (1995). Aneugenic effect of sodium arsenite on human lymphocytes in vitro: An individual susceptibility effect detected. Mutat. Res. 334, 365-373.
121. Wang, T.S., and Huang, H. (1994). Active oxygen species are involved in the induction of micronuclei by arsenite in XRS-5 cells. Mutagenesis 9, 253-257.
122. Warrell, R.P., Jr., Coonley, C.J., Strauss, D.J., and Young, C.W. (1983). Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 51, 1982-1987.
123. Watson, A.Y., and Valberg, P.A. (1996). Particle-induced lung tumors in rats: Evidence for species specificity in mechanisms. In Particle Overload in the Rat Lung and Lung Cancer: Implications for Human Risk Assessment, (J.L. Mauderly and R.J. McCunney, Eds.), pp. 227-257. Taylor & Francis, Washington, DC.
124. Webb, D.R., Sipes, I.G., and Carter, D.E. (1984). In vitro solubility and in vivo toxicity of gallium arsenide. Toxicol. Appl. Pharmacol. 76, 96-104.
125. Webb, D.R., Wilson, S.E., and Carter, D.E. (1986). Comparative pulmonary toxicity of gallium arsenide, gallium(III) oxide, or arsenic(III) oxide intratracheally instilled into rats. Toxicol. Appl. Pharmacol. 82, 405-416.
126. Webb, D.R., Wilson, S.E., and Carter, D.E. (1987). Pulmonary clearance and toxicity of respirable gallium arsenide particulates intratracheally instilled into rats. Am. Ind. Hyg. Assoc. J. 48, 660-667.
127. Williams, D.A. (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27, 103-117.
128. Williams, D.A. (1972). The comparison of several dose levels with a zero dose control. Biometrics 28, 519-531.
129. 3 particles in Beagle dogs, Fischer-344 rats, and CD-1 mice. Am. Hyg. Assoc. J. 45, 377-381.
130. Wolff, R.K., Griffith, W.C., Jr., Cuddihy, R.G., Snipes, M.B., Henderson, R.F., Mauderly, J.L., and McClellan, R.O. (1989). Modeling accumulations of particles in lung during chronic inhalation exposures that lead to impaired clearance. Health Phys. 57, 61-68.
131. Woods, J.S., and Fowler, B.A. (1978). Altered regulation of mammalian hepatic heme biosynthesis and urinary porphyrin excretion during prolonged exposure to sodium arsenate. Toxicol. Appl. Pharmacol. 43, 361-371.
132. Yager, J.W., and Ostrosky-Wegman, P., Eds. (1997). Preface. Arsenic: A paradoxical human carcinogen. Mutat. Res. 386, 181-184.
133. Yamauchi, H., Takahashi, K., and Yamamura, Y. (1986). Metabolism and excretion of orally and intraperitoneally administered gallium arsenide in the hamster. Toxicology 40, 237-246.
134. Yamauchi, H., Takahashi, K., Mashiko, M., and Yamamura, Y. (1989). Biological monitoring of arsenic exposure of gallium arsenide and inorganic arsenic-exposed workers by determination of inorganic arsenic and its metabolites in urine and hair. Am. Ind. Hyg. Assoc. J. 50, 606-612.
135. Yih, L.H., Ho, I.C., and Lee, T.C. (1997). Sodium arsenite disturbs mitosis and induces chromosome loss in human fibroblasts. Cancer Res. 57, 5051-5059.
136. Zeiger, E., Haseman, J.K., Shelby, M.D., Margolin, B.H., and Tennant, R.W. (1990). Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals. Environ. Mol. Mutagen. 16 (Suppl. 18), 1-14.
137. Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1992). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. Environ. Mol. Mutagen. 19 (Suppl. 21), 2-141.